<HashMap><database>MetabolomicsWorkbench</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>http://www.metabolomicsworkbench.org/rest/study/study_id/ST000849/mwtab</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Metabolomics</omics_type><technology_type>Mass Spectrometry</technology_type><technology_type>ESI</technology_type><disease>Spinal Cord Injury</disease><species>Mus Musculus</species><full_dataset_link>http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&amp;StudyID=ST000849</full_dataset_link><study_factor>time pt:P90d | grouping:K6-/-</study_factor><study_factor>time pt:P60d | grouping:Wt</study_factor><study_factor>time pt:P90d | grouping:K6+/+</study_factor><study_factor>time pt:P21d | grouping:K6-/-</study_factor><study_factor>time pt:P21d | grouping:PAR1</study_factor><study_factor>time pt:P21d | grouping:PAR2</study_factor><study_factor>time pt:P21d | grouping:CTRL</study_factor><study_factor>time pt:P21d | grouping:K6+/+</study_factor><study_factor>time pt:P60d | grouping:PAR1-/-</study_factor><study_factor>time pt:P60d | grouping:PAR2-/-</study_factor><tissue>Spinal Cord</tissue><submitter_affiliation>Mayo Clinic</submitter_affiliation><sample_protocol>Reversed phase NEGATIVE ION MODE.</sample_protocol><repository>MetabolomicsWorkbench</repository><metabolite_name>linoleic</metabolite_name><metabolite_name>arachidonic</metabolite_name><metabolite_name>linolenic</metabolite_name><metabolite_name>stearic</metabolite_name><metabolite_name>palmitoleic</metabolite_name><metabolite_name>myristic</metabolite_name><metabolite_name>elaidic</metabolite_name><metabolite_name>EPA</metabolite_name><metabolite_name>palmitelaidic</metabolite_name><metabolite_name>palmitic</metabolite_name><metabolite_name>DHA</metabolite_name><metabolite_name>oleic</metabolite_name><data_protocol></data_protocol><name_synonyms>FFA, PAR, pbp2, acidum flufenamicum, par1, CG8201, acide flufenamique, F7D19.13, SXR, Sheath, f2r-a, PRR, dPAR1, dPar1, ThrR, dMARK, 3'-trifluoromethyldiphenylamine-2-carboxylic acid, AI482343, flufenamic acid, DmelCG8201, ONR1, CF2R, CG11960, ctak1, CG30131, CG30132, EMK, F7D19_13, dPAR-1, D15Ertd747e, anon-WO0210402.19, DPAR-1, Achless, PARq, fluphenamic acid, dPar-1, GPCR42, Function Recovery, SNQ3, BXR, alpha-trifluoro-m-tolyl)anthranilic acid, acido flufenamico, 27C1, SAR, Flufenaminsaeure, HTR, Gpr172b, N-(alpha, PXR, HLH1, l(2)k06323, Sheaths, Function Recoveries., alpha, mRFT1, Gpcr11, Cf2r, par-1, c-tak1, N-(3-trifluoromethylphenyl)anthranilic acid, PAR-2, emk1, HELIX-LOOP-HELIX 1, PAR-1, Myelin, l(2)27C1, emk-1, GPR11, 2-[3-(trifluoromethyl)anilino]benzoic acid, BcDNA:RH48823, par1b, emk-2, 2010003P03Rik, MARK, Par-1, DPar1, Par-1A, Par-2, PAR2, Par2, PAR1, Par1, Myelin Sheaths, CG16701, PHY RAPIDLY REGULATED 1, 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID, TR</name_synonyms><sample_synonyms>backward, reversed.</sample_synonyms></additional><is_claimable>false</is_claimable><name>Targeting Myelin FFA Compostion of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI</name><description/><dates><publication></publication></dates><accession>ST000849</accession><cross_references><TAXONOMY>10090</TAXONOMY></cross_references></HashMap>